• InterCure (INCR.U) has opened the first “LEMONNADE” branch in Israel as part of the “Givol” pharmacy chain
  • The pharmacy received its cannabis dispensing license from the Israeli Medical Cannabis Agency (IMCA) on April 27th
  • The branch will operate and provide services to medical cannabis patients in Jerusalem
  • The Givol pharmacy chain is the first and the leading chain of pharmacies focused on medical cannabis in Israel
  • InterCure (dba Canndoc) is the fastest-growing and most profitable Israeli cannabis company
  • InterCure (INCR.U) is down 1.81 per cent, trading at C$7.07 per share at 1:15 pm ET

InterCure (INCR.U) has opened the first “LEMONNADE” branch in Israel as part of the “Givol” pharmacy chain.

The pharmacy has officially begun operating after received its cannabis dispensing license from the Israeli Medical Cannabis Agency (IMCA) on April 27, 2021.

This is the first branch under the “LEMONNADE” brand outside of North America to begin operations. The branch will operate and provide services to the community of medical cannabis patients in Jerusalem, which has one of the highest numbers of licensed cannabis patients in Israel.

The Givol pharmacy chain is the first and the leading chain of pharmacies focused on medical cannabis in Israel. The chain currently includes ten pharmacies across Israel. In addition, the chain operates a nationwide ordering and delivery licensed service that covers the entire medical cannabis patients’ community in Israel.

Givol chain is in growth momentum and management is working to expand the chain by among other things, the acquisition of additional pharmacies and expanding to new territories including Europe.

InterCure (dba Canndoc) is the fastest-growing and most profitable Israeli cannabis company.

Canndoc, a wholly-owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

InterCure (INCR.U) is down 1.81 per cent, trading at C$7.07 per share at 1:15 pm ET.

More From The Market Online

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

Canada’s federal budget: What investors need to know

Canada’s federal budget in has sent ripples through the investor community, revealing shifts in fiscal policies and spending priorities.